Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders
申请人:Hagan James
公开号:US20070142411A1
公开(公告)日:2007-06-21
The invention concerns the use of compounds of formula (I), (II) and (III)
which are COX-2 (cyclooxygenase-2) inhibitors, and pharmaceutically acceptable salts and solates thereof, for the treatment of schizophrenic disorders. Schizophrenic disorders of the invention are to be intended schizophrenia, delusional disorders, affective disorders, autism or tic disorders, schizophreniform disorders, in particular chronic schizophrenic psychoses and schizoaffective psychoses, temporary acute psychotic disorders. Moreover, the invention is concerned with the use of a pyrimidine derivative known as COX-2 inhibitor in combination with a neuroleptic drug for the treatment of schizophrenic disorders such as those defined above.
本发明涉及使用式(I)、(II)和(III)化合物及其药学上可接受的盐和溶剂,作为COX-2(环氧合酶-2)抑制剂,用于治疗精神分裂症。本发明的精神分裂症指精神分裂症、妄想性障碍、情感障碍、自闭症或抽动障碍、类精神分裂症、特别是慢性精神分裂症和分裂情感性精神病、暂时急性精神病性障碍。此外,本发明涉及使用一种称为COX-2抑制剂的嘧啶衍生物与神经精神药物结合治疗上述定义的精神分裂症。